U.S. Infectious Respiratory Disease Diagnostics Market Worth $9.20 Billion By 2030

U.S. Infectious Respiratory Disease Diagnostics Market Growth & Trends

The U.S. infectious respiratory disease diagnostics market is expected to reach USD 9.20 billion by 2030, registering a CAGR of -10.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is anticipated to decline due to the decrease in COVID-19 testing. However, the U.S. infectious respiratory disease diagnostics market is expected to be driven by technological advancements, an increase in the prevalence of infectious respiratory diseases, and high R&D investments by the key players, government, & NGOs to develop novel & innovative products to address the increased market demand.

For instance, in January 2021, Biomedical Advanced Research and Development Authority (BARDA) funded USD 598,000 and USD 679,000 to QIAGEN LLC and DiaSorin Molecular LLC, respectively to enhance the development of COVID-19 test kits and instruments.

The introduction of innovative products used for disease diagnosis is anticipated to fuel the U.S. respiratory infectious disease market growth. In April 2020, Bio-Rad Laboratories, Inc. introduced immunoassay test kits for the diagnosis of COVID-19 patients. These were blood-based immunoassay test kits. In the initial preliminary performance of the immunoassay, the test kit demonstrated a specificity of more than 99.0% in more than 700 patients.

In addition, PerkinElmer, Inc. received approval from the U.S. FDA for the use of a T-cell select reagent test kit for the automation of its tuberculosis spot in September 2022. It uses a globally regulated enzyme-linked immunosorbent spot (ELISPOT) interferon-gamma release assay to detect latent tuberculosis infection. This ELISPOT test enables laboratories to offer accurate results to patients with latent tuberculosis. Thus, technological advancements in infectious respiratory disease diagnostics are fueling the market.

Moreover, molecular diagnostics play an important role in infectious disease testing by offering quick & effective results. According to the Centers for Disease Prevalence and Prevention (CDC), the estimated incidence rate of tuberculosis was 2.4 cases per 100,000 populations as of 2021. Similarly, according to the American Thoracic Society, pneumonia affects around 1.0 million people annually, and 50,000 die from this disease. Thus, the increasing incidence of respiratory infections is expected to drive the U.S. infectious respiratory disease diagnostics market during the study period.

On the other hand, the presence of ambiguous regulatory frameworks and high prices of diagnostics products may hamper the U.S. infectious respiratory disease diagnostics market during the study period. High costs related to molecular & immunoassay tests and lack of alternative testing products are the other major reasons for increased prices of infectious respiratory disease diagnostic products in the U.S.

However, healthcare authorities have taken steps to reduce the burden of high costs on manufacturers. EUA received from the U.S. FDA for COVID-19 tests is expected to minimize development costs and accelerate the process to increase the availability at more testing sites. Hence, a decrease in development costs is anticipated to increase the affordability of tests for healthcare providers and patients.

 Request a free sample copy or view report summary: U.S. Infectious Respiratory Disease Diagnostics Market Report

U.S. Infectious Respiratory Disease Diagnostics Market Report Highlights

• The consumables segment dominated the infectious respiratory illness diagnostics market in 2022 with a revenue share of around 65.78%, which can be attributed to high usage rates. An increase in R&D for assays and testing kits, coupled with a rise in demand for the point-of-care in addition to the counter & self-test products is expected to drive the segment growth

• Based on the sample type, the market was dominated by nasopharyngeal swabs with an estimated share of 60.61% in 2022, due to wide applications in conducting various tests such as rapid antigen detection tests, direct fluorescent antibody, and polymerase chain reaction coupled with increased demand

• In 2022, the molecular diagnostics segment dominated the infectious respiratory disease diagnostics market with a revenue share of 63.74%, due to the increased demand for RT-PCR tests used for the diagnosis of COVID-19, influenza, RSV, and others

• The COVID-19 segment dominated the U.S. infectious respiratory disease diagnostics market with a share of 91.65% in 2022, due to the high incidence, increased product approvals, and rise in R&D pertaining to innovative products. However, its share is expected to decline to 69.97% by 2030 due to the mass vaccination drives being conducted in the U.S., which, in turn, will reduce the rate of diseases

U.S. Infectious Respiratory Disease Diagnostics Market Segmentation

Grand View Research has segmented the U.S. infectious respiratory disease diagnostics market based on the product type, sample type, technology, application, and end-use:

U.S. Infectious Respiratory Disease Diagnostics Product Type Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments

  • Respiratory Measurement Devices

  • Imaging Tests

  • Other Instruments

• Consumables

• Services

U.S. Infectious Respiratory Disease Diagnostics Sample Type Outlook (Revenue, USD Million, 2018 - 2030)

• Saliva

• Nasopharyngeal Swabs (NPS)

• Anterior Nasal Swabs

• Blood

• Others

U.S. Infectious Respiratory Disease Diagnostics Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Immunoassay

• Molecular Diagnostics

• Microbiology

• Other Technologies

U.S. Infectious Respiratory Disease Diagnostics Application Outlook (Revenue, USD Million, 2018 - 2030)

• COVID-19

• Influenza

• Respiratory Syncytial Virus (RSV)

• Tuberculosis

• Streptococcus Testing

• Other Respiratory Disease Testing

U.S. Infectious Respiratory Disease Diagnostics End-Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Diagnostic Laboratories

• Physician Offices

• Other End Users

List of the key players in the U.S. infectious respiratory disease diagnostics market

• Abbott

• Koninklijke Philips N.V.

• Siemens Healthcare GmbH

• BIOMÉRIEUX

• Danaher

• QIAGEN

• BD

• F. Hoffmann-La Roche Ltd

• Quidel Corporation

• Thermo Fisher Scientific, Inc.